Clinical Trial Update: Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder [Phase 4]

View source ↗

Summary

Phase 4 clinical trial of transdermal oxybutynin (Oxytrol) for overactive bladder has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder
• Urinary Incontinence

Drugs mentioned

• OXYTROL (OXYBUTYNIN)

Snippet

Sponsor: Watson Pharmaceuticals | Conditions: Overactive Bladder, Urinary Incontinence | Phase 4 | Status: COMPLETED